CION Ameerpet
Low-grade serous is one of the less common ovarian cancers, and the word low in its name misleads almost everyone who hears it. It is not a gentler version of high-grade serous — it is a separate disease, with a different origin, a different pace and a different treatment plan. Understanding that difference is what stops a protocol built for the commoner subtype being applied to it by default.
The name does two jobs. Serous describes the cell type, which resembles the lining of the fallopian tube — the same family as the far commoner high-grade serous carcinoma. Low-grade means that under the microscope the cells look relatively uniform and are dividing slowly.
It is tempting to read that as a milder version of the same cancer. That is not what it is, and the misunderstanding is the commonest one after this diagnosis. Low-grade serous arises from a different precursor lesion, carries different molecular drivers, is diagnosed at a younger average age, and is treated differently. Two diseases that share a surname.
The honest trade-off runs in both directions. Slow growth means this cancer is often lived with over a much longer timescale than the high-grade subtype implies. It also means chemotherapy — which works best against rapidly dividing cells — does considerably less here. Complete surgery and hormonal treatment carry weight that platinum-based chemotherapy carries in the commoner subtype.
Resembling the lining of the fallopian tube. Shared with high-grade serous — and that is roughly where the similarity stops.
Relatively uniform cells with few mitoses. The tumour typically grows over years rather than months.
Different precursor, different molecular drivers, different average age, different treatment plan. Two diseases, not two grades.
Serous ovarian cancers were graded on a single three-tier scale until the early 2000s, when a two-tier system based on nuclear atypia and mitotic rate separated them into low-grade and high-grade. The WHO Classification of Tumours now treats these as two distinct diseases rather than two grades of one, and the molecular evidence backs the split: high-grade serous carries a TP53 mutation in almost every case, while low-grade serous is typically TP53 wild-type and instead carries alterations in the MAPK signalling pathway, such as KRAS or BRAF. Different origin, different drivers, different treatment. Source: WHO Classification of Tumours — Female Genital Tumours; NCCN Ovarian Cancer guidelines.
Two cancers that share a name and very little else. Each row changes something practical about how treatment is planned.
| Feature | Low-grade serous | High-grade serous |
|---|---|---|
| How common | Uncommon — a small minority of serous ovarian cancers. | By far the commonest ovarian cancer. See high-grade serous. |
| Typical age at diagnosis | Younger on average, frequently in the thirties and forties. | Most often after the age of 50. |
| Where it comes from | Frequently arises from a serous borderline tumour of the ovary. | Usually begins at the fimbrial end of the fallopian tube. |
| Molecular signature | TP53 usually wild-type; MAPK-pathway alterations such as KRAS or BRAF are characteristic. | TP53 mutated in almost every case; roughly half show impaired DNA repair. |
| How fast it grows | Slowly. It may be present for a long time before it is found. | Quickly, spreading across the peritoneal surfaces early. |
| Response to platinum chemotherapy | Limited. Chemotherapy is not the main lever in this subtype. | Typically good. Chemotherapy is the backbone of treatment. |
| Hormone receptors | Usually oestrogen- and progesterone-receptor positive, which opens hormonal treatment. | Receptor status is far less often what decides the plan. |
| BRCA association | Uncommon. | Strong, and BRCA testing is offered to everyone with the diagnosis. |
*Both are staged with the same FIGO system, and both are often advanced when found — growing slowly does not mean being detected early, because there is no effective screening test for ovarian cancer. See the complete ovarian cancer guide.
Low-grade serous is uncommon enough that a plan built for the commoner subtype can be applied to it without anyone intending to. These questions surface that early, while it still changes something.
A report saying only serous carcinoma is worth clarifying. Low-grade and high-grade are separated on nuclear atypia and mitotic rate, and the answer changes the whole plan.
Most low-grade serous tumours are oestrogen- and progesterone-receptor positive, and that result is what opens hormonal treatment.
Completeness of surgery carries more weight here, because chemotherapy will not reliably clear what is left behind. A specific question with a specific answer.
MAPK-pathway alterations such as KRAS or BRAF are characteristic of this subtype and can point towards targeted treatment options and trials.
It is often still given, but the expected benefit is smaller than in high-grade disease. Fair to ask what it is for, and what follows it.
For an uncommon subtype a multidisciplinary review matters more, not less. Ask whether the plan was set by one clinician or by a group.
If your report gives no grade, or if nobody has mentioned hormone receptor status, both are reasonable things to raise before treatment starts rather than afterwards.
An uncommon subtype is the one most likely to be handed a plan built for a different disease. A second opinion is worth having before treatment starts rather than after it.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Chemotherapy, hormonal maintenance therapy and genetic counselling are all delivered in-house at CION.
The plan looks different from the standard ovarian cancer pathway, and the reasons are worth understanding rather than accepting on trust.
Cytoreductive surgery aims to remove all visible disease, and in low-grade serous it matters more than in almost any other ovarian cancer. In the commoner subtype, chemotherapy can often deal with small volumes of disease left behind. Here it frequently cannot, so what the surgeon achieves in theatre is much harder to make up for afterwards.
That is why who performs the operation is a reasonable thing to ask about. At CION this surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. See ovarian cancer treatment in Hyderabad for how that is arranged.
Platinum-based chemotherapy remains part of many first-line plans, particularly where disease remains after surgery. But response rates in low-grade serous are low compared with high-grade disease, for a mechanical reason rather than a mysterious one: chemotherapy acts on cells that are dividing rapidly, and these are not.
Nobody should be told that chemotherapy is pointless here — it is not, and in some situations it is clearly the right step. What should happen is a conversation about what it is expected to achieve, so the decision is made with realistic expectations rather than inherited from a protocol written for a different disease. Chemotherapy is delivered in-house at CION across more than 35 centres.
Most low-grade serous tumours are oestrogen- and progesterone-receptor positive, which means blocking that hormonal signal can slow the disease. Hormone-blocking treatment is used as maintenance after first-line treatment, and again when disease returns, and it has become one of the central options rather than a fallback.
It also suits the disease. A slow-growing cancer is well matched to a treatment taken over long periods, with a side-effect profile that is generally easier to live with than repeated chemotherapy. Read more on hormone therapy for low-grade and stromal ovarian tumours. It is delivered in-house at CION.
Because alterations in the MAPK signalling pathway — KRAS, BRAF and NRAS among them — are characteristic of this subtype, treatments that interrupt that pathway are of real interest. MEK-inhibitor-class drugs have shown activity in low-grade serous carcinoma and are an area of active clinical trials.
Molecular testing of the tumour is what identifies who might be a candidate, which is why it is worth asking whether it has been done. Where a trial is the right option, that is a discussion to have at a tumour board rather than a decision for one clinician.
A meaningful proportion of low-grade serous carcinomas are understood to arise from a serous borderline tumour, sometimes called a tumour of low malignant potential. The two are described as a continuum rather than as unrelated diagnoses.
This does not mean a borderline tumour usually becomes cancer — most do not. It does mean a past borderline diagnosis deserves proper follow-up rather than a discharge letter, and that if a new pelvic mass or new symptoms appear years later, that history is directly relevant and should be mentioned.
Recurrence is common, and it is better to know that in advance than to meet it as a shock. Because the disease is slow, recurrence in low-grade serous is often managed over years rather than treated as an endpoint, and women frequently move through several lines of treatment in that time.
The options at recurrence differ from the high-grade pathway. Repeat surgery is considered more often, hormonal treatment is used again, and trial options aimed at the MAPK pathway are reviewed. What shapes the choice is where the disease has returned, how much of it there is, and what has been used already.
The practical risk with an uncommon subtype is not neglect — it is a default. A plan written for high-grade serous can be applied to low-grade serous without anyone deciding to, because that is the plan the pathway expects. Your first consultation at CION is free and runs to about 45 minutes, which is long enough to go through the pathology report line by line rather than accept its headline. Bring the report and any imaging.
What CION delivers in-house lines up reasonably well with what this subtype needs. Chemotherapy, hormonal maintenance therapy and genetic counselling are delivered in-house across 35+ centres in Telangana and Andhra Pradesh, so treatment and long-term follow-up can continue near where you live rather than requiring repeat trips to one city hospital. Every case that raises a question goes to a tumour board rather than being decided by a single clinician.
Cytoreductive and staging surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. We would rather say that upfront than have you discover it later — and in this subtype it matters more than usual, because chemotherapy will not reliably compensate for disease left behind. On outlook: published ovarian cancer survival figures are dominated by high-grade serous and describe this disease poorly. CION publishes its own one-year survival alongside the national figure so the comparison is visible rather than implied — 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%.
Free and unhurried. Long enough to read the pathology report properly, which is where a low-grade diagnosis is either recognised or missed.
Medical oncology, imaging and pathology reviewing together. For an uncommon subtype that matters more, not less.
Delivered across 35+ centres in Telangana and Andhra Pradesh, alongside genetic counselling, so care continues near where you live.
Staging and cytoreductive surgery at specialist gynaecologic-oncology partner centres, where it may also be billed. Stated upfront.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. These are one-year figures across the whole treated ovarian cancer population — not cure rates, not subtype-specific, and not a prediction for any individual. Discuss your own prognosis with your treating oncologist.
The name does two jobs. Serous describes the cell type, which resembles the lining of the fallopian tube — the same family as the far commoner high-grade serous carcinoma. Low-grade means that under the microscope the cells look relatively uniform and are dividing slowly. Since the early 2000s, serous ovarian cancers have been separated into two grades rather than three, on the basis of nuclear atypia and mitotic rate. That change was not cosmetic. Low-grade and high-grade serous are now understood as two distinct diseases: they arise from different precursor lesions, carry different molecular drivers, are diagnosed at different average ages and are treated differently. Reading low-grade as a milder version of the same cancer is the commonest misunderstanding after this diagnosis.
Neither answer is honest on its own, which is why it is worth spelling out. Low-grade serous grows slowly, and it is often lived with over a far longer timescale than the high-grade subtype implies. That is a genuine advantage. The trade-off is that chemotherapy works best against rapidly dividing cells, so this subtype responds much less well to platinum-based chemotherapy. Where disease is left behind after surgery, or where it returns, there is no reliably effective chemotherapy to fall back on in the way there is for high-grade disease. The picture is longer-running but harder to clear completely. What follows practically is that complete surgical removal and hormonal treatment carry more of the weight here than they do in the commoner subtype.
Chemotherapy targets cells that divide quickly. Low-grade serous divides slowly, so the same feature that makes it indolent makes it resistant. Platinum-based chemotherapy is still used in many first-line plans, particularly where disease remains after surgery, but the expected benefit is smaller than in high-grade disease and it is fair to ask what the plan expects it to achieve. Two other levers matter more. The first is surgery: removing all visible disease is the strongest single thing that can be done, because chemotherapy will not reliably clear what is left. The second is hormonal treatment — most low-grade serous tumours are oestrogen- and progesterone-receptor positive, and hormone-blocking therapy is used both as maintenance and at recurrence. Molecular testing may also identify MAPK-pathway alterations that point towards targeted options.
A meaningful proportion of low-grade serous carcinomas are understood to arise from a serous borderline tumour, also called a tumour of low malignant potential, which is why the two are described as a continuum rather than as unrelated diagnoses. That does not mean a borderline tumour usually becomes cancer. Most do not, and most women treated for one never develop anything further. What it does mean is that a past borderline tumour is a reason for proper follow-up rather than a discharge letter, and that if new symptoms or a new pelvic mass appear years later, the history is directly relevant and should be mentioned. If your pathology report describes a borderline component alongside invasive low-grade serous disease, that is a recognised pattern and worth having explained.
Read them carefully, because most of them do not describe this disease. Published ovarian cancer survival figures are dominated by high-grade serous, which accounts for the majority of cases, so a general ovarian cancer statistic is largely a high-grade serous statistic wearing a broader label. They are also historical, describing women treated years ago, and they average across every stage, subtype, age and level of general health. The figures that exist for low-grade serous specifically come from small numbers and mix women whose surgery cleared all visible disease with women whose did not, which is one of the strongest influences on outcome. CION reports 81.0% one-year survival against a national 73.7%, but that too describes a whole treated population rather than a person, and it is not a cure rate. Your own outlook is a conversation for your oncologist.
The first consultation is free and runs to about 45 minutes. Bring your pathology report and any imaging, since the grade stated on that report changes the whole plan. Chemotherapy, hormonal maintenance therapy and genetic counselling are delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, so treatment and follow-up can continue near where you live. Cytoreductive and staging surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there — and in this subtype who performs that surgery matters more than usual, because chemotherapy will not reliably compensate for disease left behind. We say that upfront rather than leaving it to be discovered later. Every case that raises a question is reviewed at a tumour board.